Vutrisiran substantially reduces rates of gastrointestinal (GI) events in patients with transthyretin cardiac amyloidosis with cardiomyopathy (ATTR-CM) compared to placebo, according to an analysis of the phase 3 HELIOS-B study.1 Presented at the Hea... [3031 chars].. reed more
